Antibodies

Study links stronger antibody responses to more severe disease, as well as more advanced age and male sex

These 10 antibodies recognize different epitopes of the SARS-CoV-2 Spike glycoprotein, nine of which are SARS-CoV-2-specific and do not cross-react with other human coronaviruses

This standard 96-well ELISA based assay is a game changer for evaluating convalescent plasma, antibody therapies and determining the effectiveness of vaccines for COVID-19

Longitudinal study of COVID-19 convalescent plasma donors sheds light on ideal timing to donate

ImmunoRank offers a faster, simpler, more cost effective way to identify high titer convalescent plasma for use in both treating covid-19 patients and for creating covid-19 hyperimmune globulins

A new SARS-CoV-2 spike protein biosensor chip was successfully deployed for simultaneous measurements of IgG, IgA, and IgM using only 2 µl of serum per patient

A key protein the virus uses to initiate infection does not operate as previously thought, researchers report

Researchers have analyzed the billions of genes that code the antibodies in a system that allows the responses to individual benign intestinal microbes to be understood

Previous reports have suggested that antibodies against the novel coronavirus are short-lived, but the rate at which they decrease has not been carefully defined